Showing 4191-4200 of 5771 results for "".
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpo
- Allergan to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021https://modernod.com/news/allergan-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-2021/2479116/Allergan announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May
- Foundation Fighting Blindness Appoints Claire M. Gelfman, PhD, as Chief Scientific Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-claire-m-gelfman-phd-as-chief-scientific-officer/2479118/Foundation Fighting Blindness announced that it has appointed Claire M. Gelfman, PhD, as chief scientific officer. In her new role, Dr. Gelfman will be responsible for leading the overarching scientific strategy for the organization with a focus on research initiati
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Oertli Launches New Silicone Application Adapterhttps://modernod.com/news/oertli-launches-new-silicone-application-adapter/2479114/Oertli announced it has released a new silicone application that is designed to allow for more user-friendly and efficient surgical preparation. The Oertli silicone application sets deliver fast injection and extraction of silicone oil, according to a company news release. The universal vi
- CHMP Recommends EU Approval of Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/chmp-recommends-eu-approval-of-enspryng-satralizumab-for-neuromyelitis-optica-spectrum-disorder-nmosd/2479111/Chugai Pharmaceutical announced that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody
- Orasis Pharmaceuticals Appoints Industry Veteran Paul Smith as President and Chief Operating Officerhttps://modernod.com/news/orasis-pharmaceuticals-appoints-industry-veteran-paul-smith-as-president-and-chief-operating-officer/2479112/Orasis Pharmaceuticals announced the appointment of Paul Smith as president and chief operating officer (COO). Mr. Smith brings over two decades of leadership in eye care. “I am excited to join Orasis Pharmaceuticals at such a pivotal time in the company’s h
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollmenthttps://modernod.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/Nicox SA announced that 102 patients in the NCX 4251 Mississippi phase 2b blepharitis clinical trial have now been randomized out of a target of 200, with topline results currently on track to be announced during Q4 2021. “Achievement of 50% enrollment in this phase 2b trial of NCX 4251 in